

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Diamond Animal Health, Inc.
USDA Vet Biologics Establishment Number	213
Product Code	1151.20
True Name	Bovine Rhinotracheitis-Virus Diarrhea Vaccine, Modified Live Virus
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Diamond Animal Health, Inc. Titanium 3 - Elanco Animal Health - Diamond Animal Health, Inc. Titanium 3 - Elanco US, Inc Diamond Animal Health, Inc. Titanium 3 - Elanco, Division Eli Lilly Canada, Inc Diamond Animal Health, Inc.
Date of Compilation Summary	August 16, 2021

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

213 1151.20 Page 1 of 7

Study Type	Efficacy		
Pertaining to	Bovine Virus Diarrhea Type 1		
Study Purpose	To demonstrate effectiveness against disease caused by bovine		
_	virus diarrhea type 1		
Product Administration	1 dose to calves 6-8 months of age.		
Study Animals	Bovine		
Challenge Description	BVDV NY-1 Strain non-cytopathic Type 1b		
Interval observed after			
challenge			
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.		
USDA Approval Date	July 14, 1998		

213 1151.20 Page 2 of 7

Study Type	Efficacy		
Pertaining to	Bovine Virus Diarrhea Virus (BVDV) Type 2		
Study Purpose	To demonstrate effectiveness against disease caused by bovine		
	virus diarrhea type 2		
Product Administration			
Study Animals	Bovine		
Challenge Description	BVDV Type 2a strain 890		
Interval observed after			
challenge			
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.		
USDA Approval Date	July 14, 1998		

213 1151.20 Page 3 of 7

Study Type	Efficacy		
Pertaining to	Infectious Bovine Rhinotracheitis (IBR) Virus		
Study Purpose	To demonstrate effectiveness against disease caused by infectious		
	bovine rhinotracheitis virus.		
Product Administration	1 dose to calves 6-8 months of age.		
Study Animals	Bovine		
Challenge Description			
Interval observed after			
challenge			
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.		
USDA Approval Date	July 13, 1998		

213 1151.20 Page 4 of 7

Study Type	Safety
Pertaining to	ALL
Study Purpose	Demonstrate safety of product under typical use conditions
Product Administration	One dose
Study Animals	Bovine
Challenge Description	NA
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	July 13, 1998

213 1151.20 Page 5 of 7

Study Type	Safety					
Pertaining to	ALL					
Study Purpose	To demonstrate sa	To demonstrate safety in pregnant cows and calves nursing				
	pregnant cows					
Product	Two doses administered subcutaneously to heifers and cows, 1					
Administration	dose prior to bree	dose prior to breeding and 1 dose during pregnancy at different				
	trimesters. Heifers and cows were confirmed to be pregnant at					
		administration during pregnancy.				
Study Animals	Heifers and cows-separate groups vaccinated during each trimester.					
	•	ıps in	each trimester wei	re maintained as controls.		
Challenge Description	NA					
Interval observed after				ding vaccination through		
challenge				hrough 4 weeks of age.		
Results	Summary of Calv	_				
	(Normal calves de	elivere	d/Total deliveries)		
		I				
	Trimester		inates	Controls		
	1		208 (96%)	205/213 (96%)		
	2		313 (96%)	293/308 (95%)		
	3		205 (94%)	195/208 (94%)		
	Total	695/	726 (96%)	693/729 (95%)		
	First Trimester (<	93 day				
			Vaccinate	Control		
	Enrolled		209	213		
	Excluded (not re	lated	1	0		
	to vaccination)					
	Aborted or stillb		6	5		
	Died at or after b	oirth	2	3		
	Second Trimester	(94-1	87 days of gestation			
	T 11 1		Vaccinate	Control		
	Enrolled		315	310		
	Excluded (not re	lated	2	2		
	to vaccination)					
	Aborted or stillb		7	9		
	Died at or after b		4	6*		
	*one death was tr	om a s	set of twins; the of	her was normal		
	T1. i1 Ti	100 24	50 1 f)		
	inira i rimester (100-23	0 days of gestation Vaccinate			
	Envolled			Control		
	Enrolled	0.4444	205	208		
	Aborted or stillb		3	4**		
	Died at or after birth 3 4** *one stillborn was from a set of twins; the other was normal					
	one dead was fi	rom a	set of twins; the o	mer was normai		

213 1151.20 Page 6 of 7

USDA Approval Date	March 5, 2013

213 1151.20 Page 7 of 7